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ABSTRACT
Objective To determine the effectiveness and cost
effectiveness of using information from circulating
biomarkers to inform the prioritisation process of patients
with stable angina awaiting coronary artery bypass graft
surgery.
Design Decision analytical model comparing four
prioritisation strategies without biomarkers (no formal
prioritisation, two urgency scores, and a risk score) and
three strategies based on a risk score using biomarkers: a
routinely assessed biomarker (estimated glomerular
filtration rate), a novel biomarker (C reactive protein), or
both. The order inwhich to performcoronary artery bypass
grafting in a cohort of patients was determined by each
prioritisation strategy, and mean lifetime costs and
quality adjusted life years (QALYs) were compared.
Data sources Swedish Coronary Angiography and
Angioplasty Registry (9935 patients with stable angina
awaiting coronary artery bypass grafting and then
followed up for cardiovascular events after the procedure
for 3.8 years), and meta-analyses of prognostic effects
(relative risks) of biomarkers.
Results The observed risk of cardiovascular events while
on the waiting list for coronary artery bypass grafting was
3 per 10000 patients per day within the first 90 days (184
events in 9935 patients). Using a cost effectiveness
threshold of £20000-£30000 (€22000-€33000;
$32000-$48000) per additional QALY, a prioritisation
strategy using a risk score with estimated glomerular
filtration rate was the most cost effective strategy (cost
per additional QALYwas <£410 comparedwith theOntario
urgency score). The impact on population health of
implementing this strategy was 800 QALYs per 100000
patients at an additional cost of £245000 to the National
Health Service. The prioritisation strategy using a risk
score with C reactive protein was associated with lower
QALYs and higher costs compared with a risk score using
estimated glomerular filtration rate.
Conclusion Evaluating the cost effectiveness of
prognostic biomarkers is important even when effects at
an individual level are small. Formal prioritisation of
patients awaiting coronary artery bypass grafting using a
routinely assessed biomarker (estimated glomerular
filtration rate) along with simple, routinely collected
clinical information was cost effective. Prioritisation
strategies based on the prognostic information conferred
by C reactive protein, which is not currently measured in
this context, or a combination of C reactive protein and
estimated glomerular filtration rate, is unlikely to be cost
effective. Thewidespread practice of using only implicit or
informal means of clinically ordering the waiting list may
be harmful and should be replaced with formal
prioritisation approaches.
INTRODUCTION
Across clinical medicine there is intense interest in the
potential of novel circulating biomarkers to provide
additional prognostic information beyond standard
clinical measures, which in turnmight help to optimise
the type, amount, timing, or targeting of subsequent
intervention for patients.1-4 While there is growing
appreciation of the need to demonstrate the clinical
impact of biomarkers for altered decision making,5
research into the effectiveness and cost effectiveness
of different strategies using biomarkers has been lack-
ing. Such evaluations are a particular challenge in the
common situation where the effects of biomarkers in
terms of both quality adjusted life years (QALYs) and
costs are likely to be smaller than those associated with
direct interventions. This suggests the importance of
considering the impact on the health populations
(rather than individual patients) of investing in one
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biomarker programme compared with alternative
investments.
Prioritising the waiting list for coronary artery
surgery6-9 is an example of a common (and politically
sensitive) clinical decision in which biomarkers might
help select patients who will benefit from an earlier
operation. Recent trials confirm that coronary artery
bypass grafting remains the standard of care for severe
coronary disease,7 and recent national data show that
the numbers of procedures remain high.10 Maximum
waiting times vary between countries (for example,
14 days for high risk patients in Canada11 and 90 days
for all patients in the United Kingdom12), with an
appreciable daily risk of death or myocardial
infarction.13 14 The effectiveness of biomarkers is deter-
mined by their ability to predict such events and they
have the potential to change the day on which coron-
ary artery bypass grafting is optimally performed.
Scores have been proposed for formal prioritisation
of waiting lists15 16 but they do not include information
on biomarkers, are not widely used, and their cost
effectiveness has not been assessed. Estimated glomer-
ular filtration rate is not only measured routinely but is
the first biomarker to be recorded in a national angio-
graphic registry of patients with stable angina. Among
the “novel” biomarkers, which are not currently
widely measured, the highly sensitive C reactive pro-
tein has the largest evidence base (77 prognostic
studies).17 Clinical guidelines recommend considera-
tion of glomerular filtration rate andC reactive protein
as circulating biomarkers18 19 but do not detail how spe-
cific clinical decisions might be influenced in light of
the measurement.
This study provides a framework for assessing
whether the costs ofmeasuringbiomarkers are justified
by benefits in terms of QALYs. We determined the
effectiveness and cost effectiveness of using estimated
glomerular filtration rate and highly sensitive C reac-
tive protein for prioritising patients with stable angina
awaiting coronary artery bypass grafting. We used a
large registry of patients awaiting coronary artery
surgery20 to estimate risk of events on the waiting list,
and meta-analyses of the prognostic effect of biomar-
kers. These were incorporated into a decision analyti-
cal model as a framework to compare the cost
effectiveness of alternative prioritisation strategies
without the use of biomarkers with those including
urgency scores,15 16 or risk scores without and with the
use of biomarkers (routine, novel, or both).
METHODS
Figure 1provides an overviewof the prioritisation strat-
egies, the analytical approach, and decision analytical
model. We compared costs and health outcomes of
seven prioritisation strategies: no formal prioritisation
(that is, usual clinical practice), urgency scores (Ontario
andNewZealandalgorithms), risk scorewithout the use
of biomarkers, and three approaches using a risk score
with biomarkers: use of either a single routinely mea-
sured biomarker, estimated glomerular filtration rate
(estimated using the Cockroft Gault or modified diet
and renal disease equations), or a novel biomarker
(highly sensitive C reactive protein), or a combination
of these twobiomarkers.The strategieswere selected for
clinical and policy relevance, spanning routine biomar-
kers themeasurement ofwhich has becomewidespread
(for example, estimated glomerular filtration rate) and
those not yet routine (for example, highly sensitive C
reactive protein). The main outcomes were lifetime
costs and QALYs, which were determined by ranking
and assigning patients a day of coronary artery bypass
grafting according to each prioritisation strategy in a
representative cohort; estimating costs and QALYs for
each patient in this cohort conditional on the assigned
day of coronary artery bypass grafting; and averaging
Patients in a representative cohort are assigned a day of CABG with different prioritisation strategies
Given assigned day of CABG, costs and quality adjusted life years (QALYs) for patients are
determined by decision analytical model where patients start in no event/no CABG state
Costs and QALYs for prioritisation strategies are determined by
averaging costs and QALYs for each patient in representative cohort
Prioritisation strategies relevant to clinical decision making using prognostic information
from routinely measured biomarkers (for example, estimated glomerular filtration rate
(eGFR)) and biomarkers not routinely measured (for example, C reactive protein (CRP))
Prioritisation strategy
No formal prioritisation
Ontario urgency score
New Zealand urgency score
Risk score without
biomarker information
Risk score with
biomarker information
Explanation
Usual clinical practice, time to coronary artery bypass grafting (CABG)
in a representative cohort of patients. Patients with short waiting time
are prioritised first
Low score indicates high risk and higher priority
High score indicates high risk and higher priority
Estimated risk of cardiovascular death, non-fatal myocardial infarction,
or non-fatal stroke. Higher risk leads to higher priority
Estimated risk of cardiovascular death, non-fatal myocardial infarction,
or non-fatal stroke including literature based estimates of biomarkers
on this risk. Higher risk leads to higher priority
Stroke/myocardial
infarction/death
before CABG
No event/no CABG
Post myocardial
infarction/no CABG
No event/post CABG
CABG day 1-90
1 3
5
2
6
6
6
4
Transitions:
1. Rates of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke on waiting list for CABG
2. Procedural risk of death, non-fatal myocardial infarction, or non-fatal stroke
3. Rates of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke after successful CABG
4. Rates of subsequent cardiovascular events while on waiting list for CABG
5. Rates of subsequent cardiovascular events after successful CABG
6. Conditional probability of a composite event being non-fatal myocardial infarction, non-fatal stroke, or
     cardiovascular death
Patients are also at risk of non-cardiovascular death at any point in model (not shown in figure)
Stroke/myocardial
infarction/death
CABG
Stroke/myocardial
infarction/death
after CABG
Post stroke/
no CABG
Death
Post myocardial
infarction/post CABG
Post stroke/
post CABG
Death
Fig 1 | Prioritisation strategies
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the costs andQALYs across all patients in the cohort for
each prioritisation strategy.
Data sources and evidence synthesis
Weestimated the risk of cardiovascular events (defined
as death from cardiovascular causes, myocardial
infarction, or stroke) while on the waiting list for cor-
onary artery bypass grafting, procedural risk, and risk
after coronary artery bypass grafting from 9935
patients in the Swedish Coronary Angiography and
Angioplasty Registry20 between 2000 and 2005. This
registry includes consecutive patients without exclu-
sion criteria in all 30 centres in Sweden. For the statis-
tical analysis we selected variables based on a
combination of statistical significance and clinical a
priori importance. We carried out systematic reviews
andmeta-analyses of the effects (relative risks) on prog-
nosis of estimated glomerular filtration rate and highly
sensitive C reactive protein by searching Medline and
Embase up to November 2008.17 Eligible studies were
defined by a population with stable coronary disease
followed up for fatal or non-fatal coronary events. The
effect of estimated glomerular filtration rate was deter-
mined using the cut point of <60 ml/min at which
chronic kidney disease is defined, and because of pre-
vious evidence that the relation between renal function
and clinical events is not linear.21 The effect of highly
sensitiveC reactive proteinwas expressed according to
the top and middle of the distribution compared with
the bottom third andwas assumed to be log-linear. The
results from the meta-analysis were incorporated into
the risk equations estimated from the dataset of the
Swedish Coronary Angiography and Angioplasty
Registry. We then applied the risk equations in the
study in twoways; as variable estimates for the decision
analytical model (in determining transition probabil-
ities), and to define the prioritisation strategies (that
includes biomarker information) used to rank patients.
Costs and health related quality of life associated with
procedures and different health states in the decision
analytical model were estimated from the literature
(table 1).
The prioritisation strategies were applied to a cohort
of patients (n=338) with complete data in the Swedish
Coronary Angiography and Angioplasty Registry,
including estimated glomerular filtration rate (which
was incorporated in 2005) and time to coronary artery
bypass grafting (required to implement a strategy of no
formal prioritisation). This cohort was representative
of the 9935 patients included in the estimation of the
risk equations for risk factors and number of diseased
vessels. Data on highly sensitive C reactive protein
were not, however, available in the Swedish Coronary
Angiography and Angioplasty Registry so we used
highly sensitive C reactive protein data from a pre-
vious study25 to develop imputation algorithms which
estimated the probabilities based on observed covari-
ates, that an individual was in the top, middle, or bot-
tom third of the highly sensitive C reactive protein
distribution. In the Swedish registry data we then aver-
aged the hazardof events in each third according to this
probability. Full details of the estimated risk equations,
systematic review, and decision analytical model are
available elsewhere.17
Cost effectiveness analysis
Using a lifetime time horizon, we undertook the cost
effectiveness analysis from a UK health service per-
spective, with costs expressed in UK sterling at 2006-
7 prices.We discounted costs andQALYs by 3.5% per
annum.26Mean costs andQALYs for the various com-
parators are presented and their cost effectiveness
compared using standard decision rules and estimating
incremental cost effectiveness ratios as appropriate.27
The incremental cost effectiveness ratio examines the
additional costs that one strategy incurs over another
and compares this with the additional health benefits.
Results are interpreted using the National Institute for
Health and Clinical Excellence (NICE) cost effective-
ness threshold range of £20 000-£30 000 per additional
QALY—we consider strategies below this threshold to
be cost effective.26
Alternative scenarios
All patients in the representative cohort waiting for
coronary artery bypass grafting were assumed to
have the procedure within a maximum waiting time,
but the order in which they had the procedure within
this period was determined by the alternative methods
of prioritisation. Since themaximumwaiting timemay
vary in different healthcare settings and may affect the
estimated cost effectiveness, we assessed the three dif-
ferent maximum waiting times of 15, 40, and 90 days.
To assess the robustness of the cost effectiveness results
we investigated several alternative scenarios, including
the cost of the biomarker tests and upper and lower
95% confidence intervals of the predictive effect of bio-
markers on cardiovascular events.
Table 1 | Cost and quality of life variables for decision analytical model
Model variables Mean value Source
Annual costs (£):
Ischaemic heart disease without an event 483 Health Technology Assessment22
First year after myocardial infarction 2201 Health Technology Assessment22
Second and subsequent years after
myocardial infarction
774 Health Technology Assessment22
First year after stroke 9845 Health Technology Assessment22
Second and subsequent years after
stroke
2597 Health Technology Assessment22
Costs:
Coronary artery bypass grafting* 8203 Department of Health23
C reactive protein test 6 Research collaborator cost
Quality of life weights:
Ischaemic heart disease 0.718 Health Technology Assessment24
First year after myocardial infarction 0.683 Health Technology Assessment24
Second and subsequent years after
myocardial infarction
0.718 Health Technology Assessment24
After stroke (combining disabling and
non-disabling stroke)
0.612 Health Technology Assessment24
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RESULTS
The rate of cardiovascular events while on the waiting
list for coronary artery bypass grafting was 3 per 10 000
patients per day within the first 90 days: 184 events in
9935 patients, with amean 59 days at risk (table 2). Risk
factors associated with an increased risk and included in
the risk equation were age, diabetes, heart failure,
infarction, and involvement of the left main coronary
artery or three vessel disease. In the Swedish data the
area under the receiver operating characteristic curve
(c statistic) was 0.68. External validation of this score
on the UK dataset showed a similar c statistic of 0.65.25
The event rate within 30 days of coronary artery bypass
grafting was about 5%, and noticeably lower thereafter
(0.7 per 10 000 patients per day based on 680 events in
6980patients over ameanof 3.8 years of follow-up). The
biomarker effects from the meta-analyses that were
incorporated into the decision models were 1.96 (95%
confidence interval 1.76 to2.17) for top thirds compared
withbottom thirds ofC reactiveprotein and2.00 (1.65 to
2.42) for patients with estimated glomerular filtration
rates <60 ml/min compared with those with rates
≥60 ml/min.
Cost effectiveness of prioritisation strategies
Three prioritisation strategies (including the use of the
risk score with C reactive protein) were excluded as
they were dominated (more costly and less effective
than one or more of the other strategies) or extendedly
dominated (a combination of other strategies being
more cost effective). Of the remaining four prioritisa-
tion strategies, using the £20 000-£30 000 per addi-
tional QALY threshold range, a risk score using
estimated glomerular filtration rate seemed cost effec-
tive irrespective ofmaximumwaiting time applied (the
incremental cost effectiveness ratios compared with
Ontario urgency score were <£410 per QALY). A
prioritisation strategy with a risk score using informa-
tion from highly sensitive C reactive protein and esti-
mated glomerular filtration rate is unlikely to be cost
effective, as the incremental cost effectiveness ratios
were well above the threshold value when compared
with a risk score using estimated glomerular filtration
rate alone (table 3). The absolute gains inQALYswere
small, as were the incremental costs. For example, the
incremental gain in outcomes from using estimated
glomerular filtration rate was estimated to be about
0.008QALYs compared with no formal prioritisation,
representing an additional three days of perfect health
(for an incremental cost of £2.45 per patient).
Figure 2 plots the difference in the assigned day of
coronary arterybypass graftingbetweennon-dominated
prioritisation strategies. When the Ontario urgency
scorewas comparedwithno formal prioritisationusing a
Table 2 | Risk of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke while on the waiting list for CABG, within first 30 days after CABG,
and long term
Risk while on waiting list for CABG* Procedural risk of CABG† Long term risk‡
No of events or
patients/Total No
of patients§
Hazard ratio
(95% CI)
Adjusted
hazard ratio
No of events or
patients/Total No
of patients§
Odds ratio
(95% CI)
No of events or
patients/Total No
of patients§
Hazard ratio
(95% CI)
Adjusted
hazard ratio
Events:
Death 83/9935 — — 90/7375 — 478/6980 — —
Myocardial infarction 84/9935 — — 224/7375 — 137/6980 — —
Stroke 30/9935 — — 106/7375 — 161/6980 — —
Death, myocardial
infarction or stroke
184/9935 — — 395/7375 — 680/6980 — —
Variables in statistical
models
Age (per year) 66.03 1.05 (1.03 to1.06) 1.05 65.71 1.04 (1.02 to1.05) 65.55 1.05 (1.04 to1.06) 1.05
Heart failure 816/9935 2.43 (1.69 to3.50) 2.45 554/7375 1.82 (1.35 to2.44) 485/6980 2.23 (1.81 to2.75) 2.25
Previous myocardial
infarction
2947/9935 1.32 (0.97 to1.80) 1.29 2124/7375 1.52 (1.22 to1.89) 1957/6980 1.15 (0.98 to1.36) 1.13
Diabetes 1432/9935 1.57 (1.11 to2.23) 1.56 1015/7375 2.00 (1.56 to2.56) 912/6980 1.68 (1.39 to2.03) 1.67
Previous stroke 598/9935 1.85 (1.21 to2.83) 1.89 422/7375 2.14 (1.55 to2.95) 372/6980 2.07 (1.63 to2.62) 2.11
Left main or three-
vessel disease
7801/9935 1.51 (0.99 to2.31) 1.51 5768/7375 1.62 (1.20 to2.18) 5426/6980 1.22 (1.00 to1.49) 1.22
CRP third:
2nd third¶ — 1.40 (1.33 to1.47) 1.40 — — 1.40 (1.33 to1.47) 1.40
3rd third¶ — 1.96 (1.76 to2.17) 1.96 — — 1.96 (1.76 to2.17) 1.96
eGFR** — 2.00 (1.65 to2.42) 2.00 — — 2.00 (1.65 to2.42) 2.00
CABG=coronary artery bypass grafting; eGRF estimated glomerular filtration rate. Hazard ratios were adjusted to ensure consistency for adjustment factors across all studies considered in
meta-analysis.
*Events occurring within 90 days of assignment of CABG, patients censored at revascularisation or 90 days, mean time at risk=59 days.
†Events occurring within 30 days of procedure.
‡Risk of events in patients without an event on waiting list or an event within 30 days after CABG, mean time at risk=3.8 years.
§Mean for continuous age variable.
¶Relative risks compared with lowest third. Based on 77 studies totalling 56 496 patients and 5798 outcome events
**<60ml/min v ≥60ml/min. Based on 12 studies totalling 31 839 patients and 1639 outcome events.
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90 daymaximumwaiting time, 48.6% of patients would
undergo surgery on average 28.2 days later and 50% of
patients on average 27.4 days sooner.When a risk score
with estimated glomerular filtration rate and highly sen-
sitive C reactive protein was compared with a risk score
using estimated glomerular filtration rate alone using a
15 day maximum waiting time (fig 2), 23.3% of patients
would undergo surgery on average 1.2 days later and
24.2% of patients an average 1.1 days sooner. Figure 2
shows that adding the novel circulating biomarker
highly sensitive C reactive protein to the routinely mea-
sured estimated glomerular filtration rate has little scope
for improved effectiveness (changing the day of coron-
ary artery bypass grafting) with 90 day maximumwaits,
and none for shorter maximumwaiting times.
Alternative scenarios
The findings of the base case scenario were not altered
by the results of alternative scenarios based on the 95%
confidence intervals for the hazard ratios of estimated
glomerular filtration rate and highly sensitive C reac-
tive protein. Using the upper confidence limit (that is,
biomarkers carrying more information) and a 90 day
maximumwaiting time, the incremental cost effective-
ness ratio of a prioritisation strategy with a risk score
using estimated glomerular filtration rate and highly
sensitive C reactive protein compared with a risk
score using estimated glomerular filtration rate alone
was £39 000 per additional QALY. Using the lower
confidence limit (that is, biomarkers carrying less infor-
mation) and a 90 day maximum waiting time, the
incremental cost effectiveness ratio of a prioritisation
strategy with a risk score using estimated glomerular
filtration rate and highly sensitive C reactive protein
comparedwith a risk score using estimated glomerular
filtration rate alone was £79 000 per additional QALY.
Comparing a risk score with estimated glomerular fil-
tration rate with the Ontario urgency score yielded an
incremental cost effectiveness ratio of £306 with the
same scenario, indicating that a risk score with esti-
mated glomerular filtration rate was still the most cost
effective prioritisation strategy.
The cost effectiveness of using novel biomarkers is
sensitive to the cost of the test itself. For example, con-
sidering a waiting time of 90 days, lowering the cost of
highly sensitive C reactive protein to £3 (£6 in the base
case analysis) reduces the incremental cost effective-
ness ratio of the risk score with estimated glomerular
filtration rate and highly sensitive C reactive protein
compared with the risk score based on estimated glo-
merluar filtration rate alone to about £29 000 per
QALY. At a cost of £2 for highly sensitive C reactive
protein, the subsequent incremental cost effectiveness
ratio decreases to below the lower bound of the NICE
threshold (about £19 000 per QALY).
DISCUSSION
Based on our prospective outcome study of over 9000
patients, we developed a risk score based on age, heart
failure, myocardial infarction, diabetes, stroke, and
coronary anatomy for predicting cardiovascular
events while on the waiting list for coronary artery
bypass grafting. In our decision model we found that
incorporation of a routinely available biomarker (esti-
mated glomerular filtration rate) to this risk score was
associated with changes in the day of assigned
Table 3 | Costs and health outcomes of prioritisation strategies together with estimated cost effectiveness ratios
Strategy
Maximum waiting time
90 days 40 days 15 days
Cost Life years QALY ICER Cost Life years QALY ICER Cost Life years QALY ICER
No formal
prioritisation
16099.77 11.6611 8.2796 16095.47 11.6845 8.2973 16093.22 11.6963 8.3062
Ontario
urgency
score
16100.00 11.6646 8.2822 88 16095.53 11.6861 8.2984 55 16093.24 11.6969 8.3066 31
New Zealand
urgency
score
16100.87 11.6663 8.2835 Extendedly
dominated*
16095.91 11.6868 8.2990 Extendedly
dominated*
16093.38 11.6972 8.3068 Extendedly
dominated*
Risk score
without
biomarker
16101.98 11.6713 8.2871 Extendedly
dominated*
16096.37 11.6891 8.3006 Extendedly
dominated*
16093.53 11.6980 8.3074 Extendedly
dominated*
Risk score
with CRP
16107.99 11.6714 8.2872 Dominated† 16102.37 11.6891 8.3007 Dominated† 16099.54 11.6980 8.3074 Dominated†
Risk score
with eGFR
16102.22 11.6721 8.2877 405 16096.47 11.6894 8.3009 380 16093.57 11.6981 8.3075 362
Risk score
with CRP
+eGFR
16108.19 11.6723 8.2878 57 842 16102.46 11.6895 8.3009 133 287 16099.57 11.6982 8.3075 374 371
QALY=quality adjusted life year; ICER=incremental cost effectiveness ratio; CRP=C reactive protein; eGFR=estimated glomerular filtration rate.
ICERs are calculated as cost per QALY.
*Combination of two other comparators has lower costs and better health outcome—for example, a combination of clinical practice and risk stratification with eGFR will always be more cost
effective than New Zealand urgency score.
†Comparator strategy has lower cost and better health outcome—for example, risk stratification with CRP is associated with lower mean QALYs and higher mean costs compared with risk
stratification with eGFR.
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coronary artery bypass grafting, leading to higher
QALYs at modest additional cost. This explicit strat-
egy of formally prioritising the waiting list was both
cost effective and robust to alternative assumptions,
including variation in the maximum waiting list times
and uncertainty in the prognostic effect of biomarkers.
Adding highly sensitive C reactive protein, a more
costly biomarker, which is not routinely measured,
seemed to add insufficient prognostic information to
be cost effective in prioritising the patients.
Interpreting incremental cost effectiveness ratios for
biomarkers
Prognostic biomarkers are not interventions them-
selves, but there are strong parallels with the inter-
pretation of the cost effectiveness of biomarkers and
interventions. For example, the average risk is reduced
with most commonly used preventive interventions in
cardiovascular disease, but the benefits for the indivi-
dual can vary and for some will be small. Similarly, for
an individual patient the additional gains in quality
adjusted survival when averaged out across all patients
were small. From the perspective of an individual
patient thismaynot seemaworthwhile gain.However,
amore policy relevant perspective is that of population
health.28 Our findings suggest that implementing the
strategy of a risk score that includes estimated glomer-
ular filtration rate could offer important gains in popu-
lation health—800 QALYs per 100 000 patients at an
additional cost of £245 000 to the National Health Ser-
vice. The critical issue is howmuchhealth is forgoneby
displacing existing services elsewhere in the NHS to
generate the funds to meet this additional cost. This is
central to the cost effectiveness threshold used by
NICE. Recent empirical work on the efficiency of dif-
ferent clinical specialties in the NHS suggests that
£245 000 taken from diabetes care would on average
displace nine life years, and fromrespiratorydisease 45
life years.29 Although life years are not the same as
QALYs, these estimates are considerably lower than
the 800 QALYs gained from the use of estimated glo-
merular filtration rate in prioritising patients awaiting
coronary artery bypass grafting. This provides evi-
dence that investing in such a biomarker prioritisation
programme would be good value for money.
Strengths of the study
Our study has several strengths. Firstly, we provide an
overall framework for assessing the cost effectiveness
of prognostic biomarkers and risk scores. Such studies
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Fig 2 | Impact of different prognostic risk scores on changing assigned day of coronary artery bypass grafting (CABG), with positive (negative) values denoting a
patient was operated on later (sooner) for a particular comparison. The impact on quality adjusted life years (QALYs) is derived from these changes in CABG
order. ICER=incremental cost effectiveness ratio, CRP=C reactive protein
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have been called for but remain rare.5 Secondly, we
incorporated data from a large national contemporary
registry of patients undergoing coronary angiography
and followed up for cardiovascular events over three
phases: while patients were on the waiting list, imme-
diately after coronary artery bypass grafting, and long
term. Thirdly, we used meta-analytical estimates of
effect, which aremore precise than those from studies,
for the contribution of individual biomarkers.
Although newmarkers may contribute more prognos-
tic information, there is a potential trade-off against the
additional costs of obtaining this information.
Limitations and research implications
Our study has limitations. Firstly, in the absence of a
pre-existing risk score for predicting events while
patients were on the waiting list, we developed a new
risk equation in our Swedish dataset and carried out
external validation in a smaller UK dataset; but this
risk score requires further validation and
refinement.30 This is a challenge given that, to our
knowledge, Sweden is currently the only country
with a national coronary angiography register—that
is, with sufficient patient numbers to estimate event
rates. Secondly, datasets recording novel biomarkers
at the time of angiography among patients awaiting
coronary artery bypass grafting are lacking, and there-
fore we imputed values for highly sensitive C reactive
protein for the patients subjected to the different prior-
itisation strategies when evaluating the decision analy-
ticalmodel.While the imputationmayhavediluted the
effect of the prioritisation strategies including highly
sensitive C reactive protein, the relative risks estimates
for C reactive protein are likely to be inflated because
of publication bias and inadequate adjustment for the
routinely recorded factors known to relate to both
highly sensitive C reactive protein and outcome
(including smoking, diabetes, obesity, and lipid
concentrations).17 Even when using the upper 95%
confidence limit for the C reactive protein effect, a
prioritisation strategy with a risk score using informa-
tion from highly sensitive C reactive protein and esti-
mated glomerular filtration rate had an incremental
cost effectiveness ratio exceeding £40 000 per QALY,
and is thus unlikely to be considered cost effective.
Thirdly, ideally meta-analysis using individual partici-
pant data31 should be used to estimate the effect of
prognostic biomarkers because of the ability to stan-
dardise control for confounders. Because of the adjust-
ment biases observed in our literature based meta-
analysis,17 were such an individual participant meta-
analysis available it is likely to find a weaker C reactive
protein effect (that is, C reactive protein would be less
effective) in prioritising patients. Fourthly, we did not
fully assess uncertainty in the decision model, because
such analyses are computationally intensive (may take
days to run). Future development of decision models
should therefore incorporate probabilistic sensitivity
analyses.31 Thiswould also enable value of information
analysis to help identify specific areas where further
research is most worthwhile to fund.32
Effectiveness of other biomarkers
Ourmodel suggests that emerging biomarkers that are
more expensive than highly sensitive C reactive pro-
teinwould need an even greater effect on assigning day
of coronary artery bypass grafting to be cost effective.
For example, the cost of brain natriuretic peptide is five
times higher than highly sensitive C reactive protein;
with the relative risks that have been reported33 it is
highly unlikely to have a sufficient impact on quality
adjusted survival to be cost effective.
The predictive ability ofmultiple biomarkers has not
been widely assessed, and to date findings are
conflicting.34 35 Findings from our model suggest that
combinations of costly biomarkers are unlikely to be
cost effective. However, information on biomarkers
already obtained in clinical practice (that is, at zero
marginal cost) might be more promising candidates
for cost effectiveness evaluation given evidence that,
for example, white cell count34 or haemoglobin con-
centration might contribute independent prognostic
information.
Varying maximum waiting times
Importantly, we found that formal prioritisation with a
risk score including estimated glomerular filtration
rate had favourable incremental cost effectiveness
ratios even when maximum waiting times were
reduced to 14 days. The most recent figures (August
2008) from the UK Department of Health suggest
that about half of the patients waiting for coronary
artery bypass grafting have been doing so for between
one and threemonths, and about half up to onemonth.
Clearly the shorter thewaiting time the less scope there
is for biomarkers to reorder the waiting list and prove
cost effective. A corollary of this is that in those coun-
tries or regionswith very longwaiting times (>90days),
highly sensitive C reactive protein might become cost
effective. Our study did not deal with whether it is bet-
ter to invest healthcare resources in using information
WHAT IS ALREADY KNOWN ON THIS TOPIC
Circulating prognostic biomarkers have been widely proposed as adjuncts to the
management of many diseases, but their costs and any impact on quality adjusted survival
are commonly smaller than those associated with interventions
The cost effectiveness of using prognostic biomarkers in any clinical setting has seldombeen
assessed
An important specific clinical example involves the use of biomarkers to improve prediction
of the risk of events in patients on the waiting list for coronary artery bypass grafting, which
could help prioritise patients according to clinical need
WHAT THIS STUDY ADDS
This study provides empirical evidence of the importance of assessing the cost effectiveness
of prognostic biomarkers
Some formal prioritisation of patients awaiting coronary artery bypass grafting is better (more
cost effective) than none
Adding C reactive protein, a non-routinely measured and more costly biomarker, may not be
cost effective in prioritising patients awaiting coronary artery bypass grafting
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onbiomarkers to achieve amore efficient prioritisation
or on initiatives to shorten overall waiting times. How-
ever, our findings suggest that even with short waiting
times some formal prioritisation is better than none.
Clinical relevance of coronary artery surgery
Coronary artery surgery plays an important part in the
management of angina pectoris because it is the only
procedure that has been shown to reduce event rates
compared with medical therapy36 or with percuta-
neous coronary intervention.7 By contrast, percuta-
neous coronary intervention has been shown to offer
no reduction in event rates compared with medical
therapy.37 Recent data from the UK suggest that the
numbers of coronary artery bypass grafting proce-
dures have increased (20 512 in 2007 and 22 846 in
2008).10 Furthermore, the characteristics of those
patients are changing, with evidence of higher risk
patients receiving coronary artery bypass grafting
(older people and those more likely to have diabetes).
Such factors tend to increase the importance of risk
scoring and prioritisation because they would be
expected to increase the event rate while waiting.
Clinical and policy implications
Specifically our findings lend support to a change in
clinical practice, with introduction of formal methods
of prioritising patients for coronary artery bypass graft-
ing. We found that usual care, in which the queue for
coronary artery bypass grafting is ordered
informally,38 might be harmful, being associated with
lower QALYs than formal prioritisation methods, and
is not cost effective. We propose that formal prioritisa-
tion scores are implemented to support (not dictate) the
scheduling of coronary artery bypass grafting proce-
dures. Several lines of evidence suggest that barriers
to implementation of formal prioritisation scores,
while real, may not be large. Firstly, use of routinely
collected data on scores for calculating the risk of
operative mortality (for example, EuroScore)39 is
already widespread; suggesting that the IT infrastruc-
ture and clinical culture for implementing scores
already exists. Secondly, “formal protocols” for prior-
itisation have recently been recommended.40
More broadly, across clinical specialties we propose
that professional societies and government policy
forming bodies such as NICE should consider cost
effectiveness in evaluating prognostic biomarker stra-
tegies using similar principles as they do for drug,
device, and other technologies. This is timely because
in 2009 NICE announced plans to coordinate the eva-
luation of innovative diagnostics used in the NHS, and
as we show heremarkers such as estimated glomerular
filtration ratemay have both diagnostic and prognostic
properties. Against the background of little previous
research evaluating the cost effectiveness of prognostic
biomarkers in relation to specific clinical decisions, we
provide a framework for their evaluation. This is an
important issue because of the burgeoning number
(>100)4 of prognostic biomarkers in coronary disease
alone, which differ in cost of measurement, and evi-
dence of incremental prognostic value.
Conclusion
A widely available biomarker (estimated glomerular
filtration rate) is cost effective when combined with
other simple risk information in prioritising patients
waiting for coronary artery bypass grafting. The prog-
nostic information conferred by highly sensitive C
reactive protein, which is not routinely measured, or
a combination of highly sensitive C reactive protein
and estimated glomerular filtration rate is unlikely to
be cost effective. Most importantly, the common prac-
tice of informally ordering the waiting for coronary
artery bypass grafting, without the aid of any formal
prioritisation strategy, is not cost effective and should
be replaced.
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